Novartis AG (NVS) - Quarterly EPS earnings growth

Novartis AG stability across various jurisdictions shields it from geopolitical risks, as confirmed by the quarterly EPS comparison on the GURU.Markets base chart, where the -69.10 mark reflects the current state. Business efficiency relies on powerful research centers in the EU and US, while the implementation of AI in digital biology accelerates the release of new therapeutic agents.

novartis.com (NVS) Year-over-year earnings per share growth for the last 12 months: for the period 07/04/2022 - 11/15/2026

Comprehensive metric breakdowns and analytics for novartis.com (NVS)

- share price and expert price forecast:

Stock Price Novartis AG|NVS - Broker Consensus Forecast

- market capitalization indicators:

Market Capitalization Novartis Corporation|NVS - Company Buyout Price

- balance sheet net asset value indicators:

Net Assets per Single Share Novartis|NVS - Accounting Capitalization|Market Capitalization to Book Value Ratio novartis.com|NVS - Company Balance Sheet Assets

- debt level and financial liquidity data:

- earnings and market multiples details:

NVS - Final Profit|Future Profit Novartis AG|NVS - Market Price to Net Income Ratio|Forward P/E Multiple novartis.com|NVS - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Novartis Corporation|NVS - Operating income before deduction of amortization|Net earnings per share for the last 12 months Novartis|NVS - Earnings per share for the trailing year|Quarterly EPS earnings growth novartis.com|NVS - Earnings growth in current year|Earnings growth forecast for next year Novartis AG

- company sales and revenue statistics:

NVS - Company Total Sales Volume|Company Projected Revenue Novartis AG|NVS - Market Cap to Revenue Ratio|Forward Price-to-Revenue Multiple Novartis|NVS - Sales Growth YoY (Last Twelve Months)

Comprehensive company analysis:Novartis Inc., NVS

For the long-term investor, Novartis AG represents an asset with high potential for fundamental stability. Quarterly EPS growth measures the percentage change in net profit per share compared to the same period last year. By analyzing the current quarterly EPS growth rate, one can assess the effectiveness of the commercialization of innovative drugs for oncology and cardiology therapies. This indicator reflects the actual conversion of R&D successes into shareholder value. The stability of this metric confirms the viability of the company's business model.

Direct competitors

LLY: Quarterly EPS earnings growth|ABBV (Abbvie) - Year-over-year earnings per share growth for the last twelve months|AZN (astrazeneca.com) - Quarterly EPS earnings growth|merck.com (MRK) - Year-over-year net earnings per share change for the last twelve months|Year-over-year earnings per share growth for the last twelve months Novo Nordisk Inc. (NVO)|Year-over-year net earnings per share change for the last twelve months Amgen Corp|Quarterly EPS earnings growth PFE (Pfizer Inc)|Net earnings per share growth for the trailing year Sanofi Group|Bristol-Myers Squibb - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year GlaxoSmithKline (GSK)|TAK: Quarterly EPS earnings growth|TEVA: Year-over-year earnings per share growth rate for the last twelve months|Year-over-year net earnings per share growth for the last 12 months RDY|Viatris Corp (VTRS) - Year-over-year net earnings per share change for the last twelve months|Quarterly EPS earnings growth ROIV|Year-over-year net earnings per share change for the last twelve months Zai Lab|Quarterly EPS earnings growth BHC (Bausch Health Companies Inc.)|COSM - Year-over-year net earnings per share growth for the last 12 months